Committed to doing business the right way to deliver the best outcomes for our stakeholders:
61 Investments and 40 Exits
/ HISTORY TIMELINE
Tom Melzer and Andy Craig explore feasibility of a St. Louis-based venture capital firm.
Jay Schmelter joins effort as co-founder, along with Melzer and Craig.
RiverVest is formed and raises Fund I. Fund I portfolio company investments lead to 16 commercial products treating patients to this day.
First two investments are made in Salient Surgical (Jay Schmelter co-founder) and CyDex Pharmaceuticals. Deals return a combined 3x invested dollars. Commercial products from both companies have helped millions of patients.
RiverVest raises Fund II. Managing Directors John McKearn, Ph.D., and Niall O’Donnell, Ph.D., join and develop a successful biopharma strategy.
RiverVest Cleveland office opens.
3×5 Special Opportunity Fund (joint venture with Portland-based Arnerich Massena) launches with a concentrated portfolio of later-stage life science and natural resources investments.
Founded by RiverVest, Fund II company Lutonix exits with 8.0x gross return, highest multiple to date.
RiverVest Fund III is raised, continuing same successful strategy as Fund II.
Sale of portfolio company Lumena Pharmaceuticals to Shire closes, representing firm’s 25th exit.
3×5 RiverVest Fund II launches with same strategy as 3×5 Special Opportunity Fund.
RiverVest San Diego office opens. Managing Director Nancy Hong, Ph.D., joins.
RiverVest Archer Seed Fund is raised.
RiverVest Fund IV is raised.
Astra-Zeneca commercializes Lokelma™, the 25th product treating patients originated in a RiverVest portfolio company (ZS Pharma).
Portfolio company Allakos completes initial public offering, one of the most successful biotech IPOs in 2018.
Managing Director Derek Rapp joins.
RiverVest celebrates 20 years investing in medical devices and biopharma.
RiverVest Fund V is raised with $275M in commitments.
St. Louis101 S. Hanley Road, Suite 1850
San Diego10996 Torreyana Road, Suite 280
Cleveland11000 Cedar Avenue
Subscribe to our newsletter